In The News
Court won’t suppress barrister’s name in sexual harassment proceedings
Class action firm breaches costs disclosure rules again, argues against penalty
Class action against Phoslock, KPMG should not wait for competing case, court told
Deputy Prime Minister sued by chief of staff who complained about bullying
Albanese government dumps misinformation bill
Pacific Werribee shopping centre owners get preliminary trial in $200M defects dispute
Katy Perry wins appeal in trade mark fight with Aussie designer
Lawyers in NSW can’t use AI to generate affidavits, witness statements, court says
Group members get nothing in RoundUp class action settlement
Second judge has rosier view of claims in class action over $85M development
Please login to bookmarkClose

As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au